Publications by authors named "G Chernin"
Background And Hypothesis: The two apolipoprotein L1 () variants, G1 and G2, are common in populations of sub-Saharan African ancestry. Individuals with two of these alleles (G1 or G2) have an increased risk for a spectrum of non-diabetic chronic kidney diseases. However, these variants are typically not observed outside of populations that self-identify as current continental Africans or having clear recent African ancestry such as, most notably, African Americans, and other large population groups in the Americas and several European countries.
View Article and Find Full Text PDFHemodialysis patients are susceptible to excess volume accumulation, particularly over the 2-day interval (long interdialytic gap), resulting in higher interdialytic weight gain (IDWG). We thought to determine whether a novel device designed to enhance fluid and salt loss by activating the eccrine sweat glands can mitigate IDWG. Patients eligible for the study were undergoing regular hemodialysis for ≥3 months, without residual renal function, and with IDWG (as a percentage of IDWG/dry body weight) ≥2.
View Article and Find Full Text PDFArticle Synopsis
- The FLOW trial investigated the effects of semaglutide on cardiovascular (CV) events and death in individuals with type 2 diabetes and chronic kidney disease (CKD).
- Results showed that semaglutide lowered the risk of CV death, non-fatal heart attacks, and strokes by 18%, and overall mortality by 20% across various levels of CKD severity.
- The beneficial effects of semaglutide were consistent regardless of kidney function, protein levels in urine, or risk classification.
Aims: Dapagliflozin was approved for use in patients with chronic kidney disease (CKD) based on results of the DAPA-CKD trial, demonstrating attenuation of CKD progression and reduced risk of cardio-renal outcomes and all-cause mortality (ACM) versus placebo, in addition to standard therapy. The study objective was to assess the potential medical care cost offsets associated with reduced rates of cardio-renal outcomes across 31 countries and regions.
Materials And Methods: A comparative cost-determination framework estimated outcome-related costs of dapagliflozin plus standard therapy versus standard therapy alone over a 3-year horizon based on the DAPA-CKD trial.